$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000106282224000046 Filed on August 02, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$1.750M	$1.647M	$317.0K
YoY Change	980.25%	419.56%	805.71%
Cost Of Revenue	$71.00K	$166.0K	$8.000K
YoY Change	914.29%	1975.0%
Gross Profit	$1.679M	$1.481M	$309.0K
YoY Change	983.23%	379.29%	782.86%
Gross Profit Margin	95.94%	89.92%	97.48%
Selling, General & Admin	$39.59M	$39.19M	$30.01M
YoY Change	22.85%	30.61%	180.82%
% of Gross Profit	2358.07%	2646.32%	9711.33%
Research & Development	$25.78M	$17.64M	$14.54M
YoY Change	46.83%	21.33%	8.87%
% of Gross Profit	1535.44%	1191.29%	4705.83%
Depreciation & Amortization	$126.0K	$139.0K	$144.0K
YoY Change	26.0%	-3.47%	34.58%
% of Gross Profit	7.5%	9.39%	46.6%
Operating Expenses	$65.37M	$56.84M	$44.55M
YoY Change	31.31%	27.58%	-285.3%
Operating Profit	-$63.69M	-$55.35M	-$44.24M
YoY Change	28.33%	25.12%	84.28%
Interest Expense	-$4.562M	-$2.211M	-$1.960M
YoY Change	-217.0%	12.81%	-378.81%
% of Operating Profit
Other Income/Expense, Net	$4.562M	$2.211M	$1.296M
YoY Change	51.81%	70.6%	953.66%
Pretax Income	-$64.81M	-$53.43M	-$44.90M
YoY Change	28.34%	18.98%	82.63%
Income Tax
% Of Pretax Income
Net Earnings	-$64.81M	-$53.43M	-$44.90M
YoY Change	28.28%	18.98%	82.63%
Net Earnings / Revenue	-3703.49%	-3244.02%	-14165.3%
Basic Earnings Per Share	-$0.18	-$0.17	-$0.22
Diluted Earnings Per Share	-$0.18	-$0.17	-$0.22
COMMON SHARES
Basic Shares Outstanding	361.5M shares	246.2M shares	204.8M shares
Diluted Shares Outstanding	361.5M shares	310.8M shares	204.8M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$258.4M	$310.0M	$256.7M
YoY Change	18.29%	20.73%	314.31%
Cash & Equivalents	$34.55M	$35.62M	$102.3M
Short-Term Investments	$223.8M	$274.3M	$154.5M
Other Short-Term Assets	$6.706M	$7.675M	$6.124M
YoY Change	56.28%	25.33%	111.46%
Inventory	$636.0K	$585.0K	$172.0K
Prepaid Expenses
Receivables	$2.895M	$2.620M	$685.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$268.6M	$320.8M	$263.7M
YoY Change	20.25%	21.66%	306.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.135M	$1.954M	$2.202M
YoY Change	0.05%	-11.26%	112.75%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$828.0K	$828.0K	$6.259M
YoY Change	11.44%	-86.77%	238.51%
Total Long-Term Assets	$52.52M	$52.51M	$53.00M
YoY Change	-1.11%	-0.93%	11.76%
TOTAL ASSETS
Total Short-Term Assets	$268.6M	$320.8M	$263.7M
Total Long-Term Assets	$52.52M	$52.51M	$53.00M
Total Assets	$321.1M	$373.4M	$316.7M
YoY Change	16.15%	17.88%	181.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.20M	$12.22M	$10.50M
YoY Change	17.99%	16.37%	42.93%
Accrued Expenses	$21.85M	$15.66M	$15.61M
YoY Change	8.01%	0.31%	64.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$36.05M	$27.88M	$26.11M
YoY Change	11.73%	6.77%	54.84%
LONG-TERM LIABILITIES
Long-Term Debt	$99.90M	$99.50M	$98.77M
YoY Change	0.64%	0.74%	317.98%
Other Long-Term Liabilities	$6.670M	$6.001M	$5.482M
YoY Change	23.52%	9.47%	447.11%
Total Long-Term Liabilities	$106.6M	$105.5M	$104.3M
YoY Change	7.36%	1.2%	323.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.05M	$27.88M	$26.11M
Total Long-Term Liabilities	$106.6M	$105.5M	$104.3M
Total Liabilities	$142.6M	$133.4M	$130.4M
YoY Change	4.12%	2.31%	214.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.933B	-$1.869B	-$1.667B
YoY Change	12.6%	12.13%	8.51%
Common Stock	$363.0K	$363.0K	$245.0K
YoY Change	48.16%	48.16%	63.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.615M	$4.615M	$2.885M
YoY Change	59.97%	59.97%	39.98%
Treasury Stock Shares
Shareholders Equity	$178.5M	$240.0M	$186.4M
YoY Change
Total Liabilities & Shareholders Equity	$321.1M	$373.4M	$316.7M
YoY Change	16.15%	17.88%	181.97%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$64.81M	-$53.43M	-$44.90M
YoY Change	28.28%	18.98%	82.63%
Depreciation, Depletion And Amortization	$126.0K	$139.0K	$144.0K
YoY Change	26.0%	-3.47%	34.58%
Cash From Operating Activities	-$53.62M	-$48.54M	-$38.12M
YoY Change	28.89%	27.34%	56.08%
INVESTING ACTIVITIES
Capital Expenditures	$307.0K	$250.0K	$139.0K
YoY Change	207.0%	79.86%
Acquisitions
YoY Change
Other Investing Activities	$53.78M	-$12.07M	-$74.47M
YoY Change	-236.83%	-83.79%	445.64%
Cash From Investing Activities	$53.47M	-$12.32M	-$74.61M
YoY Change	-236.05%	-83.48%	446.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-916.0K	-14.00K	189.0M
YoY Change	358.0%	-100.01%
NET CHANGE
Cash From Operating Activities	-53.62M	-48.54M	-38.12M
Cash From Investing Activities	53.47M	-12.32M	-74.61M
Cash From Financing Activities	-916.0K	-14.00K	189.0M
Net Change In Cash	-1.066M	-60.88M	76.27M
YoY Change	-98.69%	-179.82%	-300.34%
FREE CASH FLOW
Cash From Operating Activities	-$53.62M	-$48.54M	-$38.12M
Capital Expenditures	$307.0K	$250.0K	$139.0K
Free Cash Flow	-$53.93M	-$48.79M	-$38.26M
YoY Change	29.32%	27.54%	56.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	55926000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22465000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46345000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35617000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102271000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6001000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204783000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	204783000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	196942000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	196942000	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	93110000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4302000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	241575000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	88000	usd
CY2024Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1730000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-81000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	288867000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4859000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-175000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-53429000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-143000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	239980000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-101826000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76838000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	283000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	256000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9161000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7230000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1042000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	538000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5110000	usd
CY2024Q2	us-gaap	Other Expenses OtherExpenses	2211000	usd
	us-gaap	Other Expenses OtherExpenses	7159000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204783000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	204783000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	278113000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	278113000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	196942000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	196942000	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	117124000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3415000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	824000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-31934000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	265000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	88046000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	307000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	75000	shares
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	139034000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-44904000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	63000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4302000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	241575000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-48397000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-81000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	288867000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4859000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-175000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-53429000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-143000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	239980000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76838000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	283000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	256000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9161000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7230000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1042000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	538000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5110000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	657000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	204000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	172000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2545000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3643000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-337000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-561000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3198000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2995000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103670000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69730000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	250000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	387000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	260297000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	150998000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	138000000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	88870000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-122547000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-62515000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	89000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	139034000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	241410000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1730000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	824000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	49961000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-400000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	239369000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	188171000	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	910000	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1610000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	657000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	204000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	172000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2545000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3643000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-337000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3198000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2995000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103670000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69730000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	250000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	387000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	260297000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	138000000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	88870000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-122547000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-62515000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	89000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	139034000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	241410000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1730000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	824000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	49961000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-400000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13152000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6512000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3314000	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	910000	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	115000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	307000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	115000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	307000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div>
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	268900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	58500000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	35617000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	274347000	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	309964000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	147561000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	103000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	83000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	268900000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	35617000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	274347000	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	309964000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	22465000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	147561000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	170026000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	103000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	83000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	100000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	399000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	281000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	585000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	381000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3789000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6525000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1835000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	100000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	399000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	281000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	585000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	381000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6525000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1835000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4538000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1954000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1987000	usd
CY2024Q2	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3857000	usd
CY2024Q2	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3857000	usd
CY2023Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3705000	usd
CY2023Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3705000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9171000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9591000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9591000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1337000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1337000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2570000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	15656000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	15656000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	17157000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	17157000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	99500000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5200000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5500000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4900000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5300000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000	usd
	us-gaap	Payments For Rent PaymentsForRent	700000	usd
	us-gaap	Payments For Rent PaymentsForRent	300000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	rate
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	rate
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4538000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1954000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1987000	usd
CY2024Q2	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3857000	usd
CY2024Q2	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3857000	usd
CY2023Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3705000	usd
CY2023Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3705000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9171000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9171000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9591000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9591000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1337000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1337000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2570000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2570000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	15656000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	15656000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	17157000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	99500000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5200000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5500000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4900000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5300000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000	usd
	us-gaap	Payments For Rent PaymentsForRent	700000	usd
	us-gaap	Payments For Rent PaymentsForRent	300000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	rate
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096	rate
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	691000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	691000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1220000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	865000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	881000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	898000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4746000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9301000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3124000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	6177000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4886000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4900000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3800000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9200000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7200000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1220000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	865000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	881000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	898000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4746000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9301000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3124000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4886000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4900000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3800000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9200000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7200000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001062822-24-000046-index-headers.html	Edgar Link	pending
0001062822-24-000046-index.html	Edgar Link	pending
0001062822-24-000046.txt	Edgar Link	pending
0001062822-24-000046-xbrl.zip	Edgar Link	pending
exh103officelease.htm	Edgar Link	pending
exh103officelease001.jpg	Edgar Link	pending
exh103officelease002.jpg	Edgar Link	pending
exh103officelease003.jpg	Edgar Link	pending
exh103officelease004.jpg	Edgar Link	pending
exh103officelease005.jpg	Edgar Link	pending
exh103officelease006.jpg	Edgar Link	pending
exh103officelease007.jpg	Edgar Link	pending
exh103officelease008.jpg	Edgar Link	pending
exh103officelease009.jpg	Edgar Link	pending
exh103officelease010.jpg	Edgar Link	pending
exh103officelease011.jpg	Edgar Link	pending
exh103officelease012.jpg	Edgar Link	pending
exh103officelease013.jpg	Edgar Link	pending
exh103officelease014.jpg	Edgar Link	pending
exh103officelease015.jpg	Edgar Link	pending
exh103officelease016.jpg	Edgar Link	pending
exh103officelease017.jpg	Edgar Link	pending
exh103officelease018.jpg	Edgar Link	pending
exh103officelease019.jpg	Edgar Link	pending
exh103officelease020.jpg	Edgar Link	pending
exh103officelease021.jpg	Edgar Link	pending
exh103officelease022.jpg	Edgar Link	pending
exh103officelease023.jpg	Edgar Link	pending
exh103officelease024.jpg	Edgar Link	pending
exh103officelease025.jpg	Edgar Link	pending
exh103officelease026.jpg	Edgar Link	pending
exh103officelease027.jpg	Edgar Link	pending
exh103officelease028.jpg	Edgar Link	pending
exh103officelease029.jpg	Edgar Link	pending
exh103officelease030.jpg	Edgar Link	pending
exh103officelease031.jpg	Edgar Link	pending
exh103officelease032.jpg	Edgar Link	pending
exh103officelease033.jpg	Edgar Link	pending
exh103officelease034.jpg	Edgar Link	pending
exh103officelease035.jpg	Edgar Link	pending
exh103officelease036.jpg	Edgar Link	pending
exh103officelease037.jpg	Edgar Link	pending
exh103officelease038.jpg	Edgar Link	pending
exh103officelease039.jpg	Edgar Link	pending
exh103officelease040.jpg	Edgar Link	pending
0001062822-24-000046-index-headers.html	Edgar Link	pending
0001062822-24-000046-index.html	Edgar Link	pending
0001062822-24-000046.txt	Edgar Link	pending
0001062822-24-000046-xbrl.zip	Edgar Link	pending
exh103officelease.htm	Edgar Link	pending
exh103officelease001.jpg	Edgar Link	pending
exh103officelease002.jpg	Edgar Link	pending
exh103officelease003.jpg	Edgar Link	pending
exh103officelease004.jpg	Edgar Link	pending
exh103officelease005.jpg	Edgar Link	pending
exh103officelease006.jpg	Edgar Link	pending
exh103officelease007.jpg	Edgar Link	pending
exh103officelease008.jpg	Edgar Link	pending
exh103officelease009.jpg	Edgar Link	pending
exh103officelease010.jpg	Edgar Link	pending
exh103officelease011.jpg	Edgar Link	pending
exh103officelease012.jpg	Edgar Link	pending
exh103officelease013.jpg	Edgar Link	pending
exh103officelease014.jpg	Edgar Link	pending
exh103officelease015.jpg	Edgar Link	pending
exh103officelease016.jpg	Edgar Link	pending
exh103officelease017.jpg	Edgar Link	pending
exh103officelease018.jpg	Edgar Link	pending
exh103officelease019.jpg	Edgar Link	pending
exh103officelease020.jpg	Edgar Link	pending
exh103officelease021.jpg	Edgar Link	pending
exh103officelease022.jpg	Edgar Link	pending
exh103officelease023.jpg	Edgar Link	pending
exh103officelease024.jpg	Edgar Link	pending
exh103officelease025.jpg	Edgar Link	pending
exh103officelease026.jpg	Edgar Link	pending
exh103officelease027.jpg	Edgar Link	pending
exh103officelease028.jpg	Edgar Link	pending
exh103officelease041.jpg	Edgar Link	pending
exh103officelease042.jpg	Edgar Link	pending
exh103officelease043.jpg	Edgar Link	pending
exh103officelease044.jpg	Edgar Link	pending
exh103officelease045.jpg	Edgar Link	pending
exh103officelease046.jpg	Edgar Link	pending
exh103officelease047.jpg	Edgar Link	pending
exh103officelease048.jpg	Edgar Link	pending
exh103officelease049.jpg	Edgar Link	pending
exh103officelease050.jpg	Edgar Link	pending
exh103officelease051.jpg	Edgar Link	pending
exh103officelease052.jpg	Edgar Link	pending
exh103officelease053.jpg	Edgar Link	pending
exh103officelease054.jpg	Edgar Link	pending
exh103officelease055.jpg	Edgar Link	pending
exh103officelease056.jpg	Edgar Link	pending
exh103officelease057.jpg	Edgar Link	pending
exh103officelease058.jpg	Edgar Link	pending
exh103officelease059.jpg	Edgar Link	pending
exh103officelease060.jpg	Edgar Link	pending
exh103officelease061.jpg	Edgar Link	pending
exh103officelease062.jpg	Edgar Link	pending
exh103officelease063.jpg	Edgar Link	pending
exh103officelease064.jpg	Edgar Link	pending
exh103officelease065.jpg	Edgar Link	pending
exh103officelease066.jpg	Edgar Link	pending
exh103officelease067.jpg	Edgar Link	pending
exh103officelease068.jpg	Edgar Link	pending
exh103officelease069.jpg	Edgar Link	pending
exh103officelease070.jpg	Edgar Link	pending
exh103officelease071.jpg	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrx-20240630.htm	Edgar Link	pending
lxrx-20240630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
lxrx-20240630_def.xml	Edgar Link	unprocessable
lxrx-20240630_lab.xml	Edgar Link	unprocessable
lxrx-20240630_pre.xml	Edgar Link	unprocessable
lxrx-20240630_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
exh103officelease029.jpg	Edgar Link	pending
exh103officelease030.jpg	Edgar Link	pending
exh103officelease031.jpg	Edgar Link	pending
exh103officelease032.jpg	Edgar Link	pending
exh103officelease033.jpg	Edgar Link	pending
exh103officelease034.jpg	Edgar Link	pending
exh103officelease035.jpg	Edgar Link	pending
exh103officelease036.jpg	Edgar Link	pending
exh103officelease037.jpg	Edgar Link	pending
exh103officelease038.jpg	Edgar Link	pending
exh103officelease039.jpg	Edgar Link	pending
exh103officelease040.jpg	Edgar Link	pending
exh103officelease041.jpg	Edgar Link	pending
exh103officelease042.jpg	Edgar Link	pending
exh103officelease043.jpg	Edgar Link	pending
exh103officelease044.jpg	Edgar Link	pending
exh103officelease045.jpg	Edgar Link	pending
exh103officelease046.jpg	Edgar Link	pending
exh103officelease047.jpg	Edgar Link	pending
exh103officelease048.jpg	Edgar Link	pending
exh103officelease049.jpg	Edgar Link	pending
exh103officelease050.jpg	Edgar Link	pending
exh103officelease051.jpg	Edgar Link	pending
exh103officelease052.jpg	Edgar Link	pending
exh103officelease053.jpg	Edgar Link	pending
exh103officelease054.jpg	Edgar Link	pending
exh103officelease055.jpg	Edgar Link	pending
exh103officelease056.jpg	Edgar Link	pending
exh103officelease057.jpg	Edgar Link	pending
exh103officelease058.jpg	Edgar Link	pending
exh103officelease059.jpg	Edgar Link	pending
exh103officelease060.jpg	Edgar Link	pending
exh103officelease061.jpg	Edgar Link	pending
exh103officelease062.jpg	Edgar Link	pending
exh103officelease063.jpg	Edgar Link	pending
exh103officelease064.jpg	Edgar Link	pending
exh103officelease065.jpg	Edgar Link	pending
exh103officelease066.jpg	Edgar Link	pending
exh103officelease067.jpg	Edgar Link	pending
exh103officelease068.jpg	Edgar Link	pending
exh103officelease069.jpg	Edgar Link	pending
exh103officelease070.jpg	Edgar Link	pending
exh103officelease071.jpg	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrx-20240630.htm	Edgar Link	pending
lxrx-20240630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
lxrx-20240630_lab.xml	Edgar Link	unprocessable
lxrx-20240630_pre.xml	Edgar Link	unprocessable
lxrx-20240630_htm.xml	Edgar Link	completed
lxrx-20240630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
lxrx-20240630_cal.xml	Edgar Link	unprocessable
lxrx-20240630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2024 Q3 Form 10-Q Financial Statement

#000106282224000046 Filed on August 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2024 Q3 Form 10-Q Financial Statement

#000106282224000046 Filed on August 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx